[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337575-105":59,"doc-detail-337575-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prmt5-is-an-actionable-therapeutic-target-in-cdk46-inhibitor-resistant-errb-deficient-breast-cancer","PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer","","The article investigates why estrogen receptor-positive (ER+) breast cancers become resistant to CDK4/6 inhibitors after retinoblastoma (RB1) alterations. Using genome-wide CRISPR screening, the study identifies PRMT5 as a key molecular vulnerability in ER+/RB1-knockout models. PRMT5 inhibition blocks G1-to-S transition independent of RB and triggers FUS release from RNA polymerase II, causing Ser2 hyperphosphorylation, intron retention, and downregulation of DNA synthesis proteins. Combined PRMT5 inhibition and ER degradation synergistically suppress growth in xenografts derived from cells and patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prmt5-is-an-actionable-therapeutic-target-in-cdk46-inhibitor-resistant-errb-deficient-breast-cancer/337575/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prmt5-is-an-actionable-therapeutic-target-in-cdk46-inhibitor-resistant-errb-deficient-breast-cancer/337575.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What challenge does the study address in ER+ breast cancer?","Question",{"text":112,"@type":113},"ER+ breast cancers treated with CDK4/6 inhibitors eventually develop drug resistance and disease progression. The paper focuses on resistance associated with RB1 loss-of-function alterations and the need for effective therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers identify PRMT5?",{"text":117,"@type":113},"They used a genome-wide CRISPR screen in ER+/RB1-knockout cells to find protein arginine methyltransferase 5 (PRMT5) as a molecular vulnerability.",{"name":119,"@type":110,"acceptedAnswer":120},"What happens when PRMT5 is inhibited, and how does it connect to RNA polymerase II?",{"text":121,"@type":113},"PRMT5 inhibition blocks the G1-to-S cell cycle transition and causes growth arrest. Proteomics indicates that PRMT5 inhibition dissociates FUS from RNA polymerase II, leading to Ser2 hyperphosphorylation and intron retention, with downstream effects on DNA synthesis proteins.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337575,1790126057,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Article [https://doi.org/10.1038/s41467-024-46495-2](https://doi.org/10.1038/s41467-024-46495-2)  \nPRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deﬁcient breast cancer  \nReceived: 22 June 2023  \n\n| Accepted: 29 February 2024 |\n| --- |\n| |\n| Check for updates |\n\nChang-Ching Lin 1, Tsung-Cheng Chang 2,3, Yunguan Wang4,5, Lei Guo4, Yunpeng Gao6, Emmanuel Bikorimana 1, Andrew Lemoff 7, Yisheng V. Fang1,6, He Zhang4, Yanfeng Zhang4,8, Dan Ye1, Isabel Soria-Bretones9,  \nAlberto Servetto1,10, Kyung-min Lee 1,11, Xuemei Luo7, Joseph J. Otto 7, Hiroaki Akamatsu1,12, Fabiana Napolitano 1,10, Ram Mani 6,  \nDavid W. Cescon 9, Lin Xu 4, Yang Xie 4, Joshua T. Mendell 2,3,  \nAriella B. Hanker 1 & Carlos L. Arteaga 1   \nCDK4/6 inhibitors (CDK4/6i) have improved survival of patients with estrogen receptor-positive (ER+) breast cancer. However, patients treated with CDK4/6i eventually develop drug resistance and progress. RB1 loss-of-function alterations confer resistance to CDK4/6i, but the optimal therapy for these patients is unclear. Through a genome-wide CRISPR screen, we identify protein arginine methyltransferase 5 (PRMT5) as a molecular vulnerability in ER+/RB1-knockout breast cancer cells. Inhibition of PRMT5 blocks the G1-to-S transition in the cell cycle independent of RB, leading to growth arrest in RB1-knockout cells. Proteomics analysis uncovers fused in sarcoma (FUS) as a downstream effector of PRMT5. Inhibition of PRMT5 results in dissociation of FUS from RNA polymerase II, leading to hyperphosphorylation of serine 2 in RNA polymerase II, intron retention, and subsequent downregulation of proteins involved in DNA synthesis. Furthermore, treatment with the PRMT5 inhibitor pemrametostat and a selective ER degrader fulvestrant synergistically inhibits growth of ER+/RB-deﬁcient cell-derived and patient-derived xenografts. These ﬁndings highlight dual ER and PRMT5 blockade as a potential therapeutic strategy to overcome resistance to CDK4/6i in ER+/RB-deﬁcient breast cancer.  \nEstrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype and, as such, is the leading cause of death from this disease1,2. Recently, the approval and clinical use of CDK4/6 inhibitors (CDK4/6i) in combination with antiestrogen therapy has signiﬁcantly improved progression-free and overall survival of patients with ER+ metastatic breast cancer (MBC)3–6. Despite these advances, virtually all tumors eventually acquire resistance to this therapy, leaving patients with limited therapeutic options. The efﬁcacy ofCDK4/6i relies on an intact retinoblastoma protein (RB)/E2F transcription axis. Inhibition of CDK4/6 activity suppresses RB phosphorylation, enabling RB to  \ncouple to E2F transcription factors and block entry into the S-phase of the cell cycle7. Several clinical studies have reported a strong association between RB1 loss-of-function genomic alterations and resistance to CDK4/6i in patients with ER+MBC8–12. Recently, the CDK4/6i abemaciclib was approved as adjuvant therapy for high-risk ER+ breast cancer13. With the increased use ofCDK4/6i asthe standard-of-care for ER+ breast cancer, it is anticipated that RB-deﬁcient breast cancer will become arising patient population in need of novel therapeutic strategies.  \nArginine methylation is an ubiquitous and key post-translational modiﬁcation (PTM) catalyzed by the PRMT family of enzymes. This  \nA full list of afﬁliations appears at the end of the paper. [e-mail:](e-mail: Carlos.Arteaga@UTSouthwestern.edu)[ Carlos.Arteaga@UTSouthwestern.edu](e-mail: Carlos.Arteaga@UTSouthwestern.edu)  \nfamily consists of three types of PRMTs, all of which catalyze the formation of ω-NG-monomethyl arginine (MMA). Type I and type II PRMTs are responsible for the formation of ω-NG,NG-asymmetric dimethylarginine (ADMA) and ω-NG,N’G-symmetric dimethylarginine (SDMA), respectively, while type III PRMT catalyzes the formation of only MMA14. In mammalian cells, PRMT5 is the ","cbCaitfUAaXvxBoU","https://ap.wps.com/l/cbCaitfUAaXvxBoU","pdf",3854359,16,"English","# Abstract\n# Introduction\n# PRMT5 background and rationale\n# Results\n## Genome-wide CRISPR screen identifies PRMT5 as a molecular vulnerability in ER+/RB1-deficient breast cancer cells","[{\"question\":\"What challenge does the study address in ER+ breast cancer?\",\"answer\":\"ER+ breast cancers treated with CDK4/6 inhibitors eventually develop drug resistance and disease progression. The paper focuses on resistance associated with RB1 loss-of-function alterations and the need for effective therapies.\"},{\"question\":\"How did the researchers identify PRMT5?\",\"answer\":\"They used a genome-wide CRISPR screen in ER+/RB1-knockout cells to find protein arginine methyltransferase 5 (PRMT5) as a molecular vulnerability.\"},{\"question\":\"What happens when PRMT5 is inhibited, and how does it connect to RNA polymerase II?\",\"answer\":\"PRMT5 inhibition blocks the G1-to-S cell cycle transition and causes growth arrest. Proteomics indicates that PRMT5 inhibition dissociates FUS from RNA polymerase II, leading to Ser2 hyperphosphorylation and intron retention, with downstream effects on DNA synthesis proteins.\"}]","PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer | PDF",1790019665,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa2d23c12138971999679a63019972b2.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e608b56066e839bc8ab22030ef33747.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07f775160519813a57ea183f59895076.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecd0e99adcf93b778088859a164f9cd2.webp",980,1301]